Get started
Author

Xiaoteng Lv

Observed name: Xiaoteng LV
ORCID: 0000-0002-5853-4430
Observed ORCID: 0000-0002-5853-4430
OpenAlex ID: A5113886889
In vivo human adipose-derived mesenchymal stem cell tracking after intra-articular delivery in a rat osteoarthritis model
2016 · Meng Li, Xuan Luo, et al. · Stem Cell Research & Therapy · 119
PDF
Efficacy and Persistence of Allogeneic Adipose-Derived Mesenchymal Stem Cells Combined with Hyaluronic Acid in Osteoarthritis After Intra-articular Injection in a Sheep Model
2017 · Chenchen Feng, Xuan Luo, et al. · Tissue Engineering Part A · 83
Comparative Efficacy of Autologous Stromal Vascular Fraction and Autologous Adipose-Derived Mesenchymal Stem Cells Combined With Hyaluronic Acid for the Treatment of Sheep Osteoarthritis
2018 · Xiaoteng Lv, Jiyin He, et al. · Cell Transplantation · 62
Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
2022 · Xiaoyan Qu, Gang An, et al. · Journal for ImmunoTherapy of Cancer · 34
PDF
Multi-layer integration framework for low carbon design based on design features
2021 · Lin Kong, Liming Wang, et al. · Journal of Manufacturing Systems · 27
Safety and efficacy of a novel anti-CD20 chimeric antigen receptor (CAR)-T cell therapy in relapsed/refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL) patients after failing CD19 CAR-T therapy.
2021 · Aibin Liang, Shiguang Ye, et al. · Journal of Clinical Oncology · 22
An Anti-Bcma CAR T-Cell Therapy (C-CAR088) Shows Promising Safety and Efficacy Profile in Relapsed or Refractory Multiple Myeloma
2020 · Gang An, Weiwei Sui, et al. · Blood · 22
Energy-efficient flow-shop scheduling with the strategy of switching the power statuses of machines
2022 · Jing Guo, Liming Wang, et al. · Sustainable Energy Technologies and Assessments · 10
Developing a Novel Anti-Bcma CAR-T for Relapsed or Refractory Multiple Myeloma
2019 · Xin Yao, Shigui Zhu, et al. · Blood · 10
A ranking-based differential evolution algorithm for hybrid flow shop sustainable scheduling
2021 · Liming Wang, Lin Kong, et al. · Research Square · 1
PDF
Case Report: CD20/BCMA bispecific CAR-T therapy for progressive multiple sclerosis
2026 · Zhenfen Ling, Xia Liu, et al. · Frontiers in Immunology
PDF
A phase I study of C-CAR088, a novel humanized anti-BCMA CAR T cell therapy in relapsed/refractory multiple myeloma
2022 · Xiaoyan Qu, Gang An, et al. · Research Square
PDF
A Phase I Study of C-CAR088, a Novel Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myelomaa
2022 · Xiaoyan Qu, Gang An, et al. · SSRN Electronic Journal
Works count: 13
Citation count: 390
H-index: 9
I10-index: 9
Year
Topic
Type